Voyageur Pharmaceuticals Ltd
Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in acquiring, exploring, and developing raw materials for pharmaceutical products in the United States of America, the province of British Columbia, Canada, and the state of Utah. It develops barium and iodine-based APIs. The company offers Smooth HD, Smooth X, Smooth LD, Vision HD, Vision LD, V-Gas, and other products. The co… Read more
Voyageur Pharmaceuticals Ltd (VYYRF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of August 2025: -0.694x
Based on the latest financial reports, Voyageur Pharmaceuticals Ltd (VYYRF) has a cash flow conversion efficiency ratio of -0.694x as of August 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.00 Million) by net assets ($1.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Voyageur Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Voyageur Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Voyageur Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Voyageur Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MARYGOLD COMP. DL-001
F:TF8
|
N/A |
|
Kingsmen Creatives Ltd
PINK:KMNCF
|
0.043x |
|
XIIlab Co. Ltd.
KQ:189330
|
-0.006x |
|
CKX Lands Inc
NYSE MKT:CKX
|
0.013x |
|
Dish TV India Limited
PINK:DTTVY
|
-0.042x |
|
Delta Resources Ltd
PINK:DTARF
|
-0.513x |
|
Medion AG
XETRA:MDN
|
-0.009x |
|
Malton Bhd
KLSE:6181
|
-0.051x |
Annual Cash Flow Conversion Efficiency for Voyageur Pharmaceuticals Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Voyageur Pharmaceuticals Ltd from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-11-30 | $449.96K | $-302.29K | -0.672x | +2.69% |
| 2023-11-30 | $1.44 Million | $-991.25K | -0.690x | +41.17% |
| 2022-11-30 | $1.46 Million | $-1.72 Million | -1.174x | -35.22% |
| 2021-11-30 | $1.91 Million | $-1.65 Million | -0.868x | +2.33% |
| 2020-11-30 | $306.33K | $-272.19K | -0.889x | -5.05% |
| 2019-11-30 | $754.09K | $-637.81K | -0.846x | +11.07% |
| 2018-11-30 | $515.68K | $-490.45K | -0.951x | -113.60% |
| 2017-11-30 | $-89.24K | $-624.24K | 6.995x | +13473.35% |
| 2016-11-30 | $670.46K | $-35.07K | -0.052x | +94.07% |
| 2015-11-30 | $80.07K | $-70.65K | -0.882x | -204.17% |
| 2014-11-30 | $81.56K | $-23.66K | -0.290x | +6.71% |
| 2013-11-30 | $176.02K | $-54.73K | -0.311x | -3070.28% |
| 2012-11-30 | $221.34K | $2.32K | 0.010x | +106.87% |
| 2011-11-30 | $185.00K | $-28.19K | -0.152x | -- |